IBS - Irritable Bowel Syndrome
Conditions
Brief summary
Ethosuximide and pentoxifylline in the treatment of abdominal pain related to irritable bowel syndrome
Detailed description
Ethosuximide and pentoxifylline in the treatment of abdominal pain related to irritable bowel syndrome: Does this add to current treatment?
Interventions
DRUGpentoxyifylline
Pentoxyifylline two times daily for 3 months
DRUGMebeverine
Mebeverine 3 times for 3 months
DRUGethosuximide
ethosuximide 3 times for 3 months
Sponsors
Tanta University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* • Age ≥ 18 years, * Man and Women, Negative pregnancy test and effective contraception, * IBS defined by the Rome criteria IV * During the previous seven days the inclusion visit, average numeric rating scale (NRS) pain ≥ 4. * IBS Treatment stable for 1 month
Exclusion criteria
* • Breastfeeding * Diabetic patients * Significant liver function abnormalities (transaminases\> 3N, cholestasis) and moderate renal disease (MDRD \<60 ml / min) * Addiction to alcohol and / or drugs, * Antiepileptic drugs taken (epilepsy or chronic pain) * Chronic pain of greater intensity than that related to IBS, * Known Allergyto succinimides (ethosuximide, methsuximide, phensuximide) and pentoxifylline. * History or current severe depression (hospitalization, long-term antidepressant treatment) * Psychotic disorders,
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with improved Visual analog scales (VAS) for assessment of pain in IBS | 6 months | the number of patients with improved Visual analog scales (VAS) for assessment of pain in IBS |
Countries
Egypt
Contacts
Primary ContactSherief Abd-Elsalam, ass. prof.
Outcome results
None listed